Drug Profile
Research programme: antibacterial and antiviral therapeutics - BioSource Pharm
Alternative Names: BSP-123A; BSP-C812; BSPC-705 antibiotics; BSPC-728 antibiotics; BSPC-801 antibioticsLatest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator BioSource Pharm
- Class Lipopeptides; Macrolides; Polymixins; Sulfonamides
- Mechanism of Action Cell wall inhibitors; Protein synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Bacterial infections
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Bacterial-infections in USA
- 20 Jan 2011 Preclinical development is ongoing in USA
- 20 Jan 2011 Antibacterial therapeutics are available for licensing as of 20 Jan 2011. http://www.biosourcepharm.com/